The Neurology Report

The BuyandBill.com Neurology Report is published quarterly and provides an overview of pricing trends and pipeline information for neurology drugs. Our focus is on drugs that treat multiple sclerosis, Alzheimer’s disease, myasthenia gravis, Parkinson’s disease, ALS, and other neurologic conditions.

The Q2 2025 Neurology Report from BuyandBill.com provides an analysis of HCPCS coding, ASP, WAC, and pricing trends for office-administered neurologic therapies across six key disease areas: multiple sclerosis, Alzheimer’s disease, myasthenia gravis, ALS, Parkinson’s disease, and botulinum toxin treatments. It highlights newly assigned codes, dosing schedules, ASP-to-WAC ratios, and annual treatment costs for each drug. The report emphasizes the importance of monitoring ASP changes quarterly, given their direct impact on reimbursement from Medicare and commercial payers. It also draws attention to the low level of discounting across most drug classes, particularly in emerging treatment categories.

Notable market dynamics include the entry of biosimilars in multiple sclerosis and Alzheimer’s categories, with drugs like TYRUKO and KISUNLA reshaping competition. The Alzheimer’s treatment landscape shows stable ASP trends, though KISUNLA’s arrival could pressure pricing long-term. Botulinum toxin products remain largely undiscounted, with minimal ASP fluctuation, while Parkinson’s therapies exhibit variation in ASP/WAC ratios. Myasthenia gravis therapies such as VYVGART and RYSTIGGO are priced close to list, reflecting minimal competition. ALS treatments RADICAVA and QALSODY show stable pricing as well.

The report concludes with a pipeline review, identifying therapies in development phases across all six focus areas. These include Phase 3 trials for products like Vidofludimus Calcium (MS), Donanemab (Alzheimer’s), Nipocalimab (Myasthenia Gravis), and SPN-830 (Parkinson’s). ALS and Alzheimer’s show robust early-stage development pipelines, indicating likely market evolution. The drug pipeline review helps stakeholders anticipate pricing shifts and therapeutic competition in the neurology space.